Ultragenyx Pharmaceutical | RARE - Current Assets


Ultragenyx Pharmaceutical reported $657M in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.1B 33.9M Mar/2026
Agios Pharmaceuticals USD 717.67M 117.18M Jun/2026
Alnylam Pharmaceuticals USD 4.62B 400.86M Jun/2026
BioCryst Pharmaceuticals USD 373.62M 30.72M Mar/2026
BioMarin Pharmaceutical USD 4.61B 651.58M Mar/2026
Immunic USD 188.76M 165.89M Mar/2026
Insmed USD 1.61B 181.04M Mar/2026
Ionis Pharmaceuticals USD 2.49B 446.73M Jun/2026
Karyopharm Therapeutics USD 126.33M 23.19M Mar/2026
Kyowa Hakko Kirin JPY 517.76B 57.88B Jun/2026
MacroGenics USD 182.52M 37.42M Mar/2026
Moderna USD 5.82B 45M Jun/2026
Neurocrine Biosciences USD 1.64B 798.6M Jun/2026
PTC Therapeutics USD 2.62B 363.36M Jun/2026
Puma Biotechnology USD 143.58M 7M Sep/2025
Regeneron Pharmaceuticals USD 18.45B 236.8M Jun/2026
Sarepta Therapeutics USD 2.31B 228.06M Mar/2026
Ultragenyx Pharmaceutical USD 657M 294M Mar/2026
Vertex Pharmaceuticals USD 12.54B 813.4M Jun/2026